{"id":775605,"date":"2023-08-04T12:58:40","date_gmt":"2023-08-04T16:58:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/"},"modified":"2023-08-04T12:58:40","modified_gmt":"2023-08-04T16:58:40","slug":"ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/","title":{"rendered":"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>AC Immune<\/strong><br \/>\n        <strong>Reports <\/strong><br \/>\n        <strong>Second<\/strong><br \/>\n        <strong> Quarter 2023 Financial Results and Provides a Corporate Update<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer\u2019s disease (AD)<\/li>\n<li style=\"text-align:justify\">Enrollment in ongoing Phase 1b\/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clearance, dosed first individual with DS<\/li>\n<li style=\"text-align:justify\">Next interim safety and immunogenicity data from AD and DS cohorts in ABATE expected in H2 2023<\/li>\n<li style=\"text-align:justify\">Results of amyloid plaque reduction analysis (Abeta-PET) after treatment with ACI-24.060 in ABATE study expected in H1 2024; these results could potentially provide an opportunity to accelerate into a registrational program<\/li>\n<li style=\"text-align:left\">Cash position of CHF 93.0 million finances the Company into Q3 2024, excluding the benefit of anticipated milestone payments\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Lausanne, Switzerland,<\/strong><br \/>\n        <strong>August <\/strong><br \/>\n        <strong>4<\/strong><br \/>\n        <strong>,<\/strong><br \/>\n        <strong>202<\/strong><br \/>\n        <strong>3<\/strong> \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the second quarter ended June 30, 2023, and provided a corporate update.<\/p>\n<p align=\"justify\">\n        <strong>Dr.\u00a0Andrea Pfeifer, CEO\u00a0of<\/strong>\u00a0<strong>AC Immune SA, <\/strong><strong>commented:<\/strong>\u00a0\u201cWe entered the second half of 2023 with strong momentum. ACI-24.060\u2019s Fast Track designation acknowledges its potential as a next-generation anti-Abeta active immunotherapy positioned to offer best-in-class efficacy, an improved safety profile, and fewer administration and distribution constraints compared to monoclonal antibodies. With our ABATE trial enrolling AD patients in Europe and expanding the DS cohort via US sites, ACI-24.060 is moving expeditiously towards additional interim safety and immunogenicity data, and Abeta-PET imaging analyses on amyloid plaque reduction in AD in the first half of 2024. Demonstration of Abeta plaque clearance, a validated surrogate marker for clinical efficacy, would provide a major opportunity to rapidly transition to a registrational program.\u201d<\/p>\n<p align=\"justify\">\u201cWe also look forward to the initiation of the next AD trial of ACI-35.030, the anti-pTau (phosphorylated Tau) active immunotherapy later this year, to be followed by a milestone payment. The progress of our programs affirms our commitment to developing precision medicine approaches to improve outcomes for patients, and ultimately, to prevent progression of neurodegenerative diseases through earlier diagnosis and early intervention.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Q2<\/strong><br \/>\n        <strong> 2023 <\/strong><br \/>\n        <strong>and Subsequent<\/strong><br \/>\n        <strong> Highlights<\/strong>\n      <\/p>\n<ul type=\"square\">\n<li style=\"text-align:justify\">\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\">R<\/a><br \/>\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\">eceived<\/a><br \/>\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\">Fast <\/a><br \/>\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\">Track <\/a><br \/>\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\">d<\/a><br \/>\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\">esignation<\/a> from the U.S. Food and Drug Administration (FDA) for ACI-24.060, AC Immune\u2019s wholly-owned SupraAntigen<sup>\u00ae<\/sup>-based anti-Abeta active immunotherapy candidate, for the treatment of AD.<\/li>\n<li style=\"text-align:justify\">Ongoing Phase 1b\/2 ABATE study of ACI-24.060 in patients with AD and individuals with DS is on track and <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\">expanding to sites in the U<\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\">SA<\/a> following FDA Investigational New Drug (IND) clearance.<\/li>\n<li style=\"text-align:left\">The <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\">first participant with <\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\">DS<\/a><a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-receives-fda-fast-track-designation-anti-amyloid-beta\" rel=\"nofollow noopener\" target=\"_blank\"> was dosed<\/a> in the Phase 1b\/2 ABATE trial.<\/li>\n<li style=\"text-align:left\">The first patient with Parkinson\u2019s disease was dosed in the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, AC Immune\u2019s wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy.<\/li>\n<li style=\"text-align:justify\">Several programs were <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-showcasing-precision-medicine-programs-aaic-2023\" rel=\"nofollow noopener\" target=\"_blank\">showcased<\/a> at the annual Alzheimer\u2019s Association International Conference (AAIC 2023), which included a poster detailing ABATE\u2019s trial design, a \u201cPerspectives Session\u201d focused on TDP-43 proteinopathy in neurodegenerative diseases organized by AC Immune scientists, and an oral presentation showing detailed data on ACI-12589, a novel positron emission tomography (PET) tracer targeting a-syn.<\/li>\n<li style=\"text-align:justify\">The TDP-43-PET tracer program has progressed as planned and a clinical candidate has been selected. Over the coming months further preclinical work will be completed to permit the initiation of a first in human study in 2024.<\/li>\n<li style=\"text-align:justify\">A peer-reviewed paper describing our therapeutic antibody candidate targeting TDP-43 was publishedpublished in the journal \u2018mAbs\u2019.<\/li>\n<li style=\"text-align:justify\">Initiated a research collaboration with Prof. Michael Heneka, director of the Luxembourg Centre for Systems Biomedicine, University of Luxembourg, to further evaluate the therapeutic potential of AC Immune\u2019s SupraAntigen<sup>\u00ae<\/sup>&#8211; and Morphomer<sup>\u00ae<\/sup>-derived inhibitors of the NLRP3-ASC inflammasome pathway in preclinical disease models.<\/li>\n<li style=\"text-align:justify\">Hosted a webinar on early diagnosis and prevention of AD featuring presentations by key opinion leaders Kaj Blennow, MD, PhD,\u00a0of University of Gothenburg and Sahlgrenska University Hospital, and Giovanni Frisoni, MD,\u00a0of University of Geneva and the Memory Clinic at Geneva University Hospital. To view a replay of the webinar, click <a href=\"https:\/\/lifescievents.com\/event\/ac-immune-event\/\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>.<\/li>\n<li style=\"text-align:justify\">\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-sa-appoints-new-chief-medical-officer\" rel=\"nofollow noopener\" target=\"_blank\">Announced<\/a> the appointment of new Chief Medical Officer, Nuno Mendon\u00e7a, MD.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Anticipated Milestones<\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"width:131.6px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">ACI-24.060<br \/>anti-Abeta active immunotherapy<\/td>\n<td style=\"width:443.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Additional interim safety and immunogenicity data from AD cohorts of ABATE study expected in H2 2023<\/li>\n<li style=\"text-align:left\">Interim safety and immunogenicity data from DS cohort of ABATE study expected in H2 2023<\/li>\n<li style=\"text-align:left\">Initial Abeta-PET data on amyloid plaque reduction in AD expected in H1 2024<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.6px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">ACI-7104.056<br \/>anti-a-syn active immunotherapy<\/td>\n<td style=\"width:443.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Completion of recruitment of first cohort in the Phase 2 VacSYn study in Parkinson\u2019s disease expected in H2 2023<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.6px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">ACI-35.030<br \/>anti-pTau active immunotherapy<\/td>\n<td style=\"width:443.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Initiation of next trial in AD expected in H2 2023 (to be followed by a milestone payment)<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.6px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">Semorinemab<br \/>anti-Tau antibody<\/td>\n<td style=\"width:443.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Results from the open-label extension of the Phase 2 Lauriet trial in mild-to-moderate AD expected in H2 2023<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.6px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">Anti-TDP-43 antibody<\/td>\n<td style=\"width:443.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Advancement of candidate into preclinical development (tox) expected in H2 2023<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:131.6px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: middle\">a-syn-PET tracer<\/td>\n<td style=\"width:443.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">Declaration of next clinical candidate for development in Parkinson\u2019s disease expected in H2 2023<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Analysis of Financial Statements for the Quarter Ended\u00a0<\/strong><br \/>\n        <strong>June 30<\/strong><br \/>\n        <strong>, 2023<\/strong>\n      <\/p>\n<ul type=\"square\">\n<li style=\"margin-bottom:10pt;text-align:justify\">\n          <strong>Cash Position:<\/strong> The Company ended Q2 with a total cash balance of CHF 93.0 million (CHF 122.6 million as of December 31, 2022), composed of CHF 40.0 million in cash and cash equivalents and CHF 53.0 million in short-term financial assets. The Company\u2019s cash balance provides sufficient capital resources to progress into at least Q3 2024 without considering receipt of potential future milestone payments.<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">\n          <strong>R&amp;D Expenditures:<\/strong> R&amp;D expenses for the three months ended June 30, 2023, were CHF 13.7 million compared to CHF 15.7 million in the comparable period in 2022. The decrease was due mainly to lower discovery and preclinical expenses.<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">\n          <strong>G&amp;A Expenditures:<\/strong> G&amp;A decreased by CHF 0.7 million to CHF 3.7 million, mostly due to a decrease in personnel expenses.<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">\n          <strong>Other Operating Income:<\/strong> The Company recognized CHF 0.3 million in grant income from Michael J. Fox Foundation and Target ALS grants.<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">\n          <strong>IFRS Loss for the Period:<\/strong> The Company reported a net loss after taxes of CHF 16.8 million for the three months ended June 30, 2023, compared with a net loss of CHF 19.6 million for the comparable period in 2022.<\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About AC Immune SA <\/strong><br \/>\n        <br \/>AC Immune SA\u00a0is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigen<sup>\u00ae<\/sup>\u00a0and Morphomer<sup>\u00ae<\/sup>, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3.\u00a0AC Immune\u00a0has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including\u00a0Genentech, a member of the Roche Group, Eli Lilly and Company, and\u00a0others, resulting in substantial non-dilutive funding to advance its proprietary programs and &gt;$3\u00a0billion\u00a0in potential milestone payments.<\/p>\n<p align=\"justify\">SupraAntigen<sup>\u00ae<\/sup>\u00a0is a registered trademark of\u00a0AC Immune SA\u00a0in the following territories: AU, EU, CH, GB, JP, RU, SG and\u00a0USA. Morphomer<sup>\u00ae<\/sup>\u00a0is a registered trademark of\u00a0AC Immune SA\u00a0in CN, CH, GB, JP, KR, NO and RU.<\/p>\n<p align=\"justify\">The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:450pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:281.4px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Head of <\/strong><br \/>\n            <strong>Investor Relations<\/strong><br \/>\n            <strong> &amp; Corporate Communications<\/strong><br \/>\n            <br \/>Gary Waanders, Ph.D., MBA<br \/>AC Immune<br \/>Phone: +41 21 345 91 91<br \/>Email: <a href=\"mailto:gary.waanders@acimmune.com\" rel=\"nofollow noopener\" target=\"_blank\">gary.waanders@acimmune.com<\/a><\/p>\n<\/td>\n<td style=\"width:318.6px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>U.S. Investors<\/strong><br \/>\n            <br \/>Corey Davis, Ph.D.<br \/>LifeSci Advisors<br \/>Phone: +1 212 915 2577 <br \/>Email: <a href=\"mailto:cdavis@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:281.4px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>International Media<\/strong><br \/>\n            <br \/>Chris Maggos<br \/>Cohesion Bureau<br \/>Phone: +41 79 367 6254<br \/>Email: <a href=\"mailto:chris.maggos@cohesionbureau.com\" rel=\"nofollow noopener\" target=\"_blank\">chris.maggos@cohesionbureau.com<\/a><\/p>\n<\/td>\n<td style=\"width:318.6px;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Forward looking statements<\/strong><br \/>\n        <br \/>This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the\u00a0Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and\u00a0AC Immune\u00a0does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n<p align=\"center\">\n        <strong>Condensed Consolidated Balance Sheets (Unaudited)<\/strong><br \/>\n        <br \/>\n        <strong>(In CHF thousands)<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td colspan=\"3\" style=\"width:13.94%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>As\u00a0of<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>June\u00a030,\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>December\u00a031,\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2022<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Assets<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Non-current assets<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Property, plant and equipment<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,760<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,259<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Right-of-use assets<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,539<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,808<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Intangible asset<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">50,416<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">50,416<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Long-term financial assets<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">361<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">361<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total non-current assets<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">57,076<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">57,844<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Current assets<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Prepaid expenses<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">5,167<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,708<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Accrued income<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">675<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">408<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Other current receivables<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">303<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">392<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Short-term financial assets<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">53,000<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">91,000<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Cash and cash equivalents<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">40,007<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">31,586<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total current assets<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">99,152<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">128,094<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total assets <\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">156,228<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">185,938<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Shareholders&#8217; equity and liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Shareholders\u2019 equity<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Share capital<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,800<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,797<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Share premium<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">433,699<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">431,323<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Treasury shares<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">(110)<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">(124)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Currency translation differences<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">(6)<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">10<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Accumulated losses<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(296,055)<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(264,015)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total shareholders\u2019 equity<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">139,328<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">168,991<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Non-current liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Long-term lease liabilities<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,976<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,253<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Net employee defined-benefit liabilities<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">3,771<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">3,213<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total non-current liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">5,747<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">5,466<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Current liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Trade and other payables<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,352<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">929<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Accrued expenses<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">8,818<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">9,417<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Deferred income<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">430<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">587<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Short-term lease liabilities<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">553<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">548<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total current liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">11,153<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">11,481<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">16,900<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">16,947<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total shareholders\u2019 equity and liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">156,228<\/td>\n<td style=\"width:1.11%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">185,938<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <strong>Condensed Consolidated Statements of Income\/(Loss) (Unaudited)<\/strong><br \/>\n        <br \/>(<strong>In CHF thousands, except for per-share data)<\/strong><\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:9.71%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>For the Three Months<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:9.71%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>For the Six Months<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:9.71%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Ended June\u00a030,\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:9.71%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Ended June\u00a030,\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2022<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Revenue<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Contract revenue<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total revenue<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Operating expenses<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Research &amp; development expenses<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(13,682)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(15,692)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(27,555)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(30,815)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">General &amp; administrative expenses<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(3,681)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(4,374)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(7,787)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(8,550)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Other operating income\/(expense), net<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">317<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">207<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">725<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">677<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total operating expenses<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(17,046)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,859)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(34,617)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(38,688)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Operating loss<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(17,046)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,859)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(34,617)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(38,688)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Financial income<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">259<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">468<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Financial expense<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(27)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(126)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(124)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(279)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Exchange differences<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(16)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">345<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(67)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">485<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Finance result, net<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">216<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">219<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">277<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">206<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Loss before tax<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(16,830)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,640)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(34,340)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(38,482)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">Income tax expense<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(3)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(3)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(6)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Loss for the period<\/strong>\n          <\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(16,833)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,643)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(34,346)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(38,489)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:28.39%;text-align: left;vertical-align: middle;vertical-align: bottom\">Loss per share:<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.20)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.23)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.41)<\/td>\n<td style=\"width:1.09%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:4.31%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.46)<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <strong>Condensed Consolidated Statements of Comprehensive Income\/(Loss) (Unaudited)<\/strong><br \/>\n        <br \/>\n        <strong>(In CHF thousands)<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:30.72%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:30.72%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:8.66%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>For the Three Months<\/strong>\n          <\/td>\n<td style=\"width:0.98%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:8.66%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>For the Six Months<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:30.72%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:8.66%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Ended June\u00a030,\u00a0<\/strong>\n          <\/td>\n<td style=\"width:0.98%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:8.66%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Ended June\u00a030,\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:30.72%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:3.84%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:0.98%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:3.84%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:0.98%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:3.84%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:0.98%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:3.84%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2022<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:30.72%;text-align: left;vertical-align: middle;vertical-align: bottom\">Loss for the period<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">(16,833)<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,643)<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">(34,346)<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">(38,489)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:30.72%;text-align: left;vertical-align: middle;vertical-align: bottom\">Items that will be reclassified to income or loss in subsequent periods (net of tax):<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:30.72%;text-align: left;vertical-align: middle;vertical-align: bottom\">Currency translation differences<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">(8)<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">39<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">(16)<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">49<\/td>\n<\/tr>\n<tr>\n<td style=\"width:30.72%;text-align: left;vertical-align: middle;vertical-align: bottom\">Items that will not to be reclassified to income or loss in subsequent periods (net of tax):<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:30.72%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Remeasurement gains on defined-benefit plans<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">7,381<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">7,381<\/td>\n<\/tr>\n<tr>\n<td style=\"width:30.72%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Total comprehensive loss (net of tax)<\/strong>\n          <\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(16,841)<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(12,223)<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(34,362)<\/td>\n<td style=\"width:0.98%;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:3.84%;border-bottom: double 15px 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(31,059)<\/td>\n<\/tr>\n<\/table>\n<p \/>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/68f8a1d2-cb5c-4ef7-abfe-f6f4fe087af6\" rel=\"noopener\">20230804_ACIU_Q2_Earnings_Final<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ODAyMDQwNWItNTMwMi00YzBiLThiODUtNmVmNWZhMDZiYzgxLTEwMzc0NDM=\/tiny\/AC-Immune-SA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer\u2019s disease (AD) Enrollment in ongoing Phase 1b\/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clearance, dosed first individual with DS Next interim safety and immunogenicity data from AD and DS cohorts in ABATE expected in H2 2023 Results of amyloid plaque reduction analysis (Abeta-PET) after treatment with ACI-24.060 in ABATE study expected in H1 2024; these results could potentially provide an opportunity to accelerate into a registrational program Cash position of CHF 93.0 million finances the Company into Q3 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-775605","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer\u2019s disease (AD) Enrollment in ongoing Phase 1b\/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clearance, dosed first individual with DS Next interim safety and immunogenicity data from AD and DS cohorts in ABATE expected in H2 2023 Results of amyloid plaque reduction analysis (Abeta-PET) after treatment with ACI-24.060 in ABATE study expected in H1 2024; these results could potentially provide an opportunity to accelerate into a registrational program Cash position of CHF 93.0 million finances the Company into Q3 &hellip; Continue reading &quot;AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-04T16:58:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update\",\"datePublished\":\"2023-08-04T16:58:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/\"},\"wordCount\":1709,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/\",\"name\":\"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ==\",\"datePublished\":\"2023-08-04T16:58:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Market Newsdesk","og_description":"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer\u2019s disease (AD) Enrollment in ongoing Phase 1b\/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clearance, dosed first individual with DS Next interim safety and immunogenicity data from AD and DS cohorts in ABATE expected in H2 2023 Results of amyloid plaque reduction analysis (Abeta-PET) after treatment with ACI-24.060 in ABATE study expected in H1 2024; these results could potentially provide an opportunity to accelerate into a registrational program Cash position of CHF 93.0 million finances the Company into Q3 &hellip; Continue reading \"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-04T16:58:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update","datePublished":"2023-08-04T16:58:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/"},"wordCount":1709,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/","name":"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ==","datePublished":"2023-08-04T16:58:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzE0NiM0MDE1OTA4MjQjMjAyNTg3MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=775605"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775605\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=775605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=775605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=775605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}